Michiel Heron1, Jan C Grutters2, Heleen van Velzen-Blad3, Marcel Veltkamp1, Anke M E Claessen3, Jules M M van den Bosch1. 1. Center for Interstitial Lung Diseases, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands. 2. Center for Interstitial Lung Diseases, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: j.grutters@antonius.net. 3. Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Abstract
BACKGROUND: Different types of immune cells are involved in the formation of granulomas, a hallmark of pulmonary sarcoidosis. Proinflammatory monocytes are activated circulating monocytes thought to be related to the initial events of granuloma formation. We tested the hypothesis that peripheral blood monocytes in patients with active pulmonary sarcoidosis have an activated phenotype and, secondly, that measuring this activation status can provide a new tool for monitoring disease activity. METHODS: Blood was collected of 23 steroid-naive patients presenting with pulmonary sarcoidosis and 10 healthy control subjects. Expression of CD16 (Fc-gamma type III receptor), CD69 (a general activation marker of cells of the hematopoietic lineage), and the integrin very late antigen (VLA)-1 (on interaction with extracellular matrix compounds mediates cell adhesion) was measured by flow cytometry. RESULTS: Percentages of monocytes expressing CD16, CD69, and VLA-1 in patients vs control subjects were 56.2 +/- 4.1% vs 12.2 +/- 2.4% (p < 0.0001), 87.3 +/- 2.1% vs 8.6 +/- 3.3% (p < 0.0001), and 66.5 +/- 3.6% vs 11.2 +/- 2.3% (p < 0.0001), respectively. Moreover, the CD69+VLA-1+ monocyte subset, abundantly present at disease presentation, was found to decrease to normal levels during follow-up with disease remission. CONCLUSIONS: Peripheral blood monocytes from patients with pulmonary sarcoidosis show a highly activated phenotype. Phenotyping circulating monocytes might be a promising tool for monitoring sarcoidosis disease activity but needs further investigation.
BACKGROUND: Different types of immune cells are involved in the formation of granulomas, a hallmark of pulmonary sarcoidosis. Proinflammatory monocytes are activated circulating monocytes thought to be related to the initial events of granuloma formation. We tested the hypothesis that peripheral blood monocytes in patients with active pulmonary sarcoidosis have an activated phenotype and, secondly, that measuring this activation status can provide a new tool for monitoring disease activity. METHODS: Blood was collected of 23 steroid-naive patients presenting with pulmonary sarcoidosis and 10 healthy control subjects. Expression of CD16 (Fc-gamma type III receptor), CD69 (a general activation marker of cells of the hematopoietic lineage), and the integrin very late antigen (VLA)-1 (on interaction with extracellular matrix compounds mediates cell adhesion) was measured by flow cytometry. RESULTS: Percentages of monocytes expressing CD16, CD69, and VLA-1 in patients vs control subjects were 56.2 +/- 4.1% vs 12.2 +/- 2.4% (p < 0.0001), 87.3 +/- 2.1% vs 8.6 +/- 3.3% (p < 0.0001), and 66.5 +/- 3.6% vs 11.2 +/- 2.3% (p < 0.0001), respectively. Moreover, the CD69+VLA-1+ monocyte subset, abundantly present at disease presentation, was found to decrease to normal levels during follow-up with disease remission. CONCLUSIONS: Peripheral blood monocytes from patients with pulmonary sarcoidosis show a highly activated phenotype. Phenotyping circulating monocytes might be a promising tool for monitoring sarcoidosis disease activity but needs further investigation.
Authors: Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold Journal: Cytokine Date: 2013-02-04 Impact factor: 3.861
Authors: Ian A Thompson; Baoying Liu; H Nida Sen; Xiadong Jiao; Robert Katamay; Zhiyu Li; Mengjun Hu; Fielding Hejtmancik; Robert B Nussenblatt Journal: Am J Ophthalmol Date: 2013-03-14 Impact factor: 5.258
Authors: Eóin C O'Brien; Wayel H Abdulahad; Abraham Rutgers; Minke G Huitema; Vincent P O'Reilly; Alice M Coughlan; Mark Harrington; Peter Heeringa; Mark A Little; Fionnuala B Hickey Journal: Sci Rep Date: 2015-07-07 Impact factor: 4.379
Authors: Daniëlle Hijdra; Adriane D M Vorselaars; Jan C Grutters; Anke M E Claessen; Ger T Rijkers Journal: Front Immunol Date: 2013-10-22 Impact factor: 7.561
Authors: Daniëlle Hijdra; Adriane Dm Vorselaars; Jan C Grutters; Anke Me Claessen; Ger T Rijkers Journal: J Inflamm (Lond) Date: 2012-10-05 Impact factor: 4.981